1-6 of 6
Abood Okal
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

INSIGHT: A baseline laboratory profile independently predicts outcomes and demonstrates superiority of lisocabtagene maraleucel (liso-cel) over standard of care (SOC) in second-line (2L) large B-cell lymphoma (LBCL) regardless of baseline profile

Free
Sahar Ansari, Manali Kamdar, Eniko Papp, Mazyar Shadman, Jeremy Abramson, Begüm D. Topçuoglu, Pei Yang, Lara Stepan, Pradipta Ray, Amanda Przespolewski, Krishna R. Juluri, Eric Bleickardt, Debasmita Roy, Alessandro Crotta, Timothy B. Campbell, Julie A. Rytlewski, Abood Okal, Ethan Thompson, Leanne Peiser
Journal: Blood
Blood (2025) 146 (Supplement 1): 1775.
https://doi.org/10.1182/blood-2025-1775
Published: 2025
Journal Articles

Lisocabtagene maraleucel (liso-cel) demonstrates superior efficacy across inflammatory risk subgroups in second-line (2L) large B-cell lymphoma (LBCL): A retrospective analysis of the TRANSFORM study

Free
Pradipta Ray, Abood Okal, Miguel-Angel Perales, Sandeep Raj, Roni Shouval, Eniko Papp, Sahar Ansari, Krishna R. Juluri, Amanda Przespolewski, Debasmita Roy, Ethan Thompson, Julie A. Rytlewski, Eric Bleickardt, Alessandro Crotta, Timothy B. Campbell, Leanne Peiser
Journal: Blood
Blood (2025) 146 (Supplement 1): 3549.
https://doi.org/10.1182/blood-2025-3549
Published: 2025
Journal Articles

Dynamics of Circulating Tumor DNA As a Predictor of Outcomes with Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma from the Transcend NHL-001 Study

Free
Dasom Lee, Brian J. Sworder, Lara Stepan, Abood Okal, Chang-Pin Huang, Xiaoman Kang, James Hamilton, Charles Macaulay, Mari Olsen, Chih Long Liu, Maximilian Diehn, Leanne Peiser, David Kurtz, Ash A. Alizadeh
Journal: Blood
Blood (2024) 144 (Supplement 1): 3410.
https://doi.org/10.1182/blood-2024-200924
Published: 2024
Journal Articles

Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study

Free
Lara Stepan, Sahar Ansari, Abood Okal, Justine Dell'Aringa, Ethan G. Thompson, Alessandro Crotta, Victor A. Chow, Jeremy S. Abramson, Manali Kamdar, Scott R. Solomon, Patrick B. Johnston, Bertram Glass, Pim Mutsaers, Jon E. Arnason, Stephan Mielke, Mazyar Shadman, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Veronika Bachanova, Sami Ibrahimi, Jacob Chabon, David Kurtz, Ash A. Alizadeh, Leanne Peiser
Journal: Blood
Blood (2024) 144 (Supplement 1): 72.
https://doi.org/10.1182/blood-2024-199813
Published: 2024
Journal Articles

Undetectable MRD Status in Patients with R/R CLL/SLL with Stable Disease after Lisocabtagene Maraleucel Treatment: Exploratory Analysis of the TRANSCEND CLL 004 Study

Free
Eniko Papp, Sahar Ansari, Jason Wall, Ethan Thompson, Yizhe Chen, Tanya Siddiqi, William G. Wierda, Serena K. Perna, Sherilyn A. Tuazon, Abood Okal, Leanne Peiser
Journal: Blood
Blood (2023) 142 (Supplement 1): 3263.
https://doi.org/10.1182/blood-2023-180230
Published: 2023
Journal Articles

Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study

Free
Lara Stepan, Sahar Ansari, Abood Okal, Justine Dell'Aringa, Ethan Thompson, Alessandro Crotta, Victor A Chow, Jeremy S. Abramson, Manali Kamdar, Jacob J. Chabon, Gregory Hogan, David M. Kurtz, Ash A. Alizadeh, Leanne Peiser
Journal: Blood
Blood (2023) 142 (Supplement 1): 225.
https://doi.org/10.1182/blood-2023-181007
Published: 2023